Source: Eur Respir J, 55 (2) 1901908; 10.1183/13993003.01908-2019
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Jan-Willem C. Alffenaar, Onno W. Akkerman, Simon Tiberi, Giovanni Sotgiu, Giovanni Battista Migliori. Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?. Eur Respir J, 55 (2) 1901908; 10.1183/13993003.01908-2019

Member's Comments

No comment yet.

Related content which might interest you: Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis Source: Eur Respir J 2016; 47: 564-574 Year: 2016 Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009 Treatment options for patients with multidrug-resistant or extensively drug-resistant tuberculosis Source: Annual Congress 2009 - Priorities in tuberculosis research Year: 2009 Multidrug- and extensively drug-resistant tuberculosis: an emerging threat Source: Eur Respir Rev 2009; 18: 195-197 Year: 2009 Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017 Year: 2017 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India Source: Eur Respir J 2012; 39: 956-962 Year: 2012 Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017 Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience Source: Eur Respir J 2016; 47: 333-336 Year: 2016 Transmission of multidrug-resistant and extensively drug-resistant tuberculosis in a metropolitan city Source: Eur Respir J 2013; 41: 901-908 Year: 2013 Risk factors for treatment failure in multidrug-resistant and extensively drug-resistant tuberculosis in Estonia Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008 High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen Source: Eur Respir J, 52 (6) 1801528; 10.1183/13993003.01528-2018 Year: 2018 First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline Source: Eur Respir J 2016; 48: 935-938 Year: 2016 The individual-tailored treatment regimens for multidrug-resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Management and treatment of multidrug-resistant tuberculosis Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management Year: 2019 Clinical and operational value of the extensively drug-resistant tuberculosis definition Source: Eur Respir J 2007; 30: 623-626 Year: 2007 Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection. Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018